Summarized by Masters of Longevity from Longevity Technology.
Partial epigenetic reprogramming inside the eye — a short news feature previewing early human safety and functional-signal data from a first-in-human trial.
Key Takeaways
- Three open-angle glaucoma patients received the starting ER-100 dose and had no serious adverse events through Day 56.
- Two patients showed visual-field improvements with at least 28% of tested points improving by more than 4 decibels at Day 56.
- The independent Data Safety Monitoring Board recommended dose escalation from 2×10^9 to 6×10^9 vector genomes.
